FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029650228> ?p ?o ?g. }

• W2029650228 endingPage "465.e9" @default.
• W2029650228 startingPage "465.e1" @default.
• W2029650228 abstract "Objective To evaluate PIK3CA mutational status and c-erbB2 gene amplification in a series of primary uterine serous carcinomas (USC) cell lines. To assess the efficacy of GDC-0980, a potent inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2), against primary USC harboring HER2/neu gene amplification and/or PIK3CA mutations. Study Design Twenty-two primary USC cell lines were evaluated for c-erbB2 oncogene amplification by fluorescence in situ hybridization (FISH) assays and for PIK3CA gene mutations by direct DNA sequencing of exons 9 and 20. In vitro sensitivity to GDC-0980 was evaluated by flow-cytometry-based viability and proliferation assays. Downstream cellular responses to GDC-0980 were assessed by measuring phosphorylation of the 4-EBP1 protein by flow-cytometry. Results Five of 22 (22.7%) USC cell lines contained oncogenic PIK3CA mutations although 9 (40.9%) harbored c-erbB2 gene amplification by FISH. GDC-0980 caused a strong differential growth inhibition in FISH+ USC when compared with FISH− (GDC-0980 IC50 mean ± SEM = 0.29 ± 0.05 μM in FISH+ vs 1.09 ± 0.20 μM in FISH− tumors, P = .02). FISH+ USC harboring PIK3CA mutations were significantly more sensitive to GDC-0980 exposure when compared with USC cell lines harboring wild-type PIK3CA (P = .03). GDC-0980 growth-inhibition was associated with a significant and dose-dependent decline in phosphorylated 4-EBP1 levels. Conclusion Oncogenic PIK3CA mutations and c-erbB2 gene amplification may represent biomarkers to identify patients harboring USC who may benefit most from the use of GDC-0980. To evaluate PIK3CA mutational status and c-erbB2 gene amplification in a series of primary uterine serous carcinomas (USC) cell lines. To assess the efficacy of GDC-0980, a potent inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2), against primary USC harboring HER2/neu gene amplification and/or PIK3CA mutations. Twenty-two primary USC cell lines were evaluated for c-erbB2 oncogene amplification by fluorescence in situ hybridization (FISH) assays and for PIK3CA gene mutations by direct DNA sequencing of exons 9 and 20. In vitro sensitivity to GDC-0980 was evaluated by flow-cytometry-based viability and proliferation assays. Downstream cellular responses to GDC-0980 were assessed by measuring phosphorylation of the 4-EBP1 protein by flow-cytometry. Five of 22 (22.7%) USC cell lines contained oncogenic PIK3CA mutations although 9 (40.9%) harbored c-erbB2 gene amplification by FISH. GDC-0980 caused a strong differential growth inhibition in FISH+ USC when compared with FISH− (GDC-0980 IC50 mean ± SEM = 0.29 ± 0.05 μM in FISH+ vs 1.09 ± 0.20 μM in FISH− tumors, P = .02). FISH+ USC harboring PIK3CA mutations were significantly more sensitive to GDC-0980 exposure when compared with USC cell lines harboring wild-type PIK3CA (P = .03). GDC-0980 growth-inhibition was associated with a significant and dose-dependent decline in phosphorylated 4-EBP1 levels. Oncogenic PIK3CA mutations and c-erbB2 gene amplification may represent biomarkers to identify patients harboring USC who may benefit most from the use of GDC-0980." @default.
• W2029650228 created "2016-06-24" @default.
• W2029650228 creator A5002826928 @default.
• W2029650228 creator A5008166734 @default.
• W2029650228 creator A5010339370 @default.
• W2029650228 creator A5026827320 @default.
• W2029650228 creator A5041993659 @default.
• W2029650228 creator A5045925318 @default.
• W2029650228 creator A5046857977 @default.
• W2029650228 creator A5049383880 @default.
• W2029650228 creator A5066823675 @default.
• W2029650228 creator A5075330842 @default.
• W2029650228 date "2013-11-01" @default.
• W2029650228 modified "2023-10-18" @default.
• W2029650228 title "Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)" @default.
• W2029650228 cites W1494567425 @default.
• W2029650228 cites W1551875882 @default.
• W2029650228 cites W1885232396 @default.
• W2029650228 cites W1984136423 @default.
• W2029650228 cites W2016294917 @default.
• W2029650228 cites W2018022997 @default.
• W2029650228 cites W2028878627 @default.
• W2029650228 cites W2036450767 @default.
• W2029650228 cites W2044869180 @default.
• W2029650228 cites W2057370954 @default.
• W2029650228 cites W2064416108 @default.
• W2029650228 cites W2065949107 @default.
• W2029650228 cites W2071989607 @default.
• W2029650228 cites W2073863379 @default.
• W2029650228 cites W2074199421 @default.
• W2029650228 cites W2093627674 @default.
• W2029650228 cites W2101587340 @default.
• W2029650228 cites W2129202918 @default.
• W2029650228 cites W2154207535 @default.
• W2029650228 cites W2161817637 @default.
• W2029650228 cites W2166405684 @default.
• W2029650228 cites W2171095731 @default.
• W2029650228 cites W2249698993 @default.
• W2029650228 doi "https://doi.org/10.1016/j.ajog.2013.07.020" @default.
• W2029650228 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23891627" @default.
• W2029650228 hasPublicationYear "2013" @default.
• W2029650228 type Work @default.
• W2029650228 sameAs 2029650228 @default.
• W2029650228 citedByCount "28" @default.
• W2029650228 countsByYear W20296502282013 @default.
• W2029650228 countsByYear W20296502282014 @default.
• W2029650228 countsByYear W20296502282015 @default.
• W2029650228 countsByYear W20296502282016 @default.
• W2029650228 countsByYear W20296502282017 @default.
• W2029650228 countsByYear W20296502282018 @default.
• W2029650228 countsByYear W20296502282019 @default.
• W2029650228 countsByYear W20296502282020 @default.
• W2029650228 crossrefType "journal-article" @default.
• W2029650228 hasAuthorship W2029650228A5002826928 @default.
• W2029650228 hasAuthorship W2029650228A5008166734 @default.
• W2029650228 hasAuthorship W2029650228A5010339370 @default.
• W2029650228 hasAuthorship W2029650228A5026827320 @default.
• W2029650228 hasAuthorship W2029650228A5041993659 @default.
• W2029650228 hasAuthorship W2029650228A5045925318 @default.
• W2029650228 hasAuthorship W2029650228A5046857977 @default.
• W2029650228 hasAuthorship W2029650228A5049383880 @default.
• W2029650228 hasAuthorship W2029650228A5066823675 @default.
• W2029650228 hasAuthorship W2029650228A5075330842 @default.
• W2029650228 hasConcept C104317684 @default.
• W2029650228 hasConcept C153911025 @default.
• W2029650228 hasConcept C184235292 @default.
• W2029650228 hasConcept C2777542201 @default.
• W2029650228 hasConcept C30481170 @default.
• W2029650228 hasConcept C501734568 @default.
• W2029650228 hasConcept C502942594 @default.
• W2029650228 hasConcept C54355233 @default.
• W2029650228 hasConcept C62478195 @default.
• W2029650228 hasConcept C81885089 @default.
• W2029650228 hasConcept C86554907 @default.
• W2029650228 hasConcept C86803240 @default.
• W2029650228 hasConceptScore W2029650228C104317684 @default.
• W2029650228 hasConceptScore W2029650228C153911025 @default.
• W2029650228 hasConceptScore W2029650228C184235292 @default.
• W2029650228 hasConceptScore W2029650228C2777542201 @default.
• W2029650228 hasConceptScore W2029650228C30481170 @default.
• W2029650228 hasConceptScore W2029650228C501734568 @default.
• W2029650228 hasConceptScore W2029650228C502942594 @default.
• W2029650228 hasConceptScore W2029650228C54355233 @default.
• W2029650228 hasConceptScore W2029650228C62478195 @default.
• W2029650228 hasConceptScore W2029650228C81885089 @default.
• W2029650228 hasConceptScore W2029650228C86554907 @default.
• W2029650228 hasConceptScore W2029650228C86803240 @default.
• W2029650228 hasIssue "5" @default.
• W2029650228 hasLocation W20296502281 @default.
• W2029650228 hasLocation W20296502282 @default.
• W2029650228 hasOpenAccess W2029650228 @default.
• W2029650228 hasPrimaryLocation W20296502281 @default.
• W2029650228 hasRelatedWork W1991523530 @default.
• W2029650228 hasRelatedWork W2002128513 @default.
• W2029650228 hasRelatedWork W2009966535 @default.
• W2029650228 hasRelatedWork W2020824267 @default.
• W2029650228 hasRelatedWork W2031436818 @default.
• W2029650228 hasRelatedWork W2057739827 @default.

• next